NCT03146377View on ClinicalTrials.gov

Study of Xeloxiri Regimen for Patients With Refractory Metastatic Colorectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Colorectal Cancer
Interventions
DRUG

Capecitabine

1250 mg/m2 BD orally for 1 week of a 2-week cycle (i.e. 1 week on, 1 week off)

DRUG

Oxaliplatin

85 mg/m2 IV on day 1 of a 2-week cycle

DRUG

Irinotecan

165 mg/m2 IV on day 1 of a 2-week cycle

Trial Locations (1)

Unknown

Queen Mary Hospital, The University of Hong Kong, Hong Kong

All Listed Sponsors
lead

The University of Hong Kong

OTHER

NCT03146377 - Study of Xeloxiri Regimen for Patients With Refractory Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter